MENLO PARK, Calif., Jan. 7, 2019 – Adicet Bio, Inc., a biopharmaceutical company focused on the development of next-generation immunotherapies, announced today that the company will present at the 37th Annual J.P. Morgan Healthcare Conference.

Donald Santel, Executive Chairman of Adicet Bio, will provide a company overview on Wednesday, January 9, 2019, at 2:00pm PT.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a privately held, pre-clinical stage biotechnology company engaged in the design and development of cutting-edge immunotherapies with initial focus on cancer. Adicet is developing novel universal immune cell therapies based on gamma delta T cells engineered with Chimeric Antigen Receptors (CARs) or T Cell Receptors (TCRs). dicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and generating TCR-like MAbs (TCRLs) directed to these cancer-specific peptide targets presented by MHC Class I complexes. These TCRLs can be used to arm T cells, as T cell engagers or as Antibody Drug Conjugates (ADC). In August 2016, Adicet entered a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop next-generation engineered immune-cell therapeutics using Adicet's gamma delta T cell allogeneic platform technology. Adicet Bio raised $51M in series A financing led by OrbiMed Partners, OrbiMed Israel, Novartis Venture Fund and Pontifax. Adicet Bio is located in Menlo Park, California.

For more information, please visit our website at http://www.adicetbio.com.

Contact:

Brian Hogan
Chief Financial Officer
650-542-0034

Anne Bowdidge
Investor Relations
650-218-6900